Table of Contents Author Guidelines Submit a Manuscript
Journal of Lipids
Volume 2014, Article ID 923903, 8 pages
http://dx.doi.org/10.1155/2014/923903
Research Article

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size

1The Medicines Company (Schweiz) GmbH, Talstrasse 59, 8002 Zürich, Switzerland
2Pacific Biomarkers LLC, 645 Elliott Avenue West, Suite 300, Seattle, WA 98119, USA
3Lipid Metabolism Laboratory, Tufts University, 711 Washington Street, Boston, MA 02111, USA
4Liposcience LLC, 2500 Sumner Boulevard, Raleigh, NC 27616, USA
5Vascular Strategies LLC, 5110 Campus Drive, Suite 150, Plymouth Meeting, PA 19462, USA

Received 30 August 2014; Revised 20 October 2014; Accepted 21 October 2014; Published 12 November 2014

Academic Editor: Akihiro Inazu

Copyright © 2014 Herman J. Kempen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Parolini, M. Marchesi, and P. Lorenzon, “Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-IMilano/1-Palmitoyl-2-Oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging,” Journal of the American College of Cardiology, vol. 51, no. 11, pp. 1098–1103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Ibanez, G. Vilahur, G. Cimmino et al., “Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis,” Journal of the American College of Cardiology, vol. 51, no. 11, pp. 1104–1109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. E. Nissen, T. Tsunoda, E. M. Tuzcu et al., “Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial,” The Journal of the American Medical Association, vol. 290, no. 17, pp. 2292–2300, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. J. Kempen, M. Gomaraschi, S. E. Bellibas et al., “Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys,” Journal of Lipid Research, vol. 54, no. 9, pp. 2341–2353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. H. Caparon, K. J. Rust, A. K. Hunter et al., “Integrated solution to purification challenges in the manufacture of a soluble recombinant protein in E. coli,” Biotechnology and Bioengineering, vol. 105, no. 2, pp. 239–249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Miida, O. Miyazaki, Y. Nakamura et al., “Analytical performance of a sandwich enzyme immunoassay for preβ1-HDL in stabilized plasma,” Journal of Lipid Research, vol. 44, no. 3, pp. 645–650, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. B. F. Asztalos, P. S. Roheim, R. L. Milani et al., “Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 12, pp. 2670–2676, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. E. J. Jeyarajah, W. C. Cromwell, and J. D. Otvos, “Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy,” Clinics in Laboratory Medicine, vol. 26, no. 4, pp. 847–870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. R. S. Rosenson, H. B. Brewer Jr., M. J. Chapman et al., “HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events,” Clinical Chemistry, vol. 57, no. 3, pp. 392–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Diditchenko, A. Gille, I. Pragst et al., “Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 9, pp. 2202–2211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Miyazaki, J. Ogihara, I. Fukamachi, and T. Kasumi, “Evidence for the presence of lipid-free monomolecular apolipoprotein a-1 in plasma,” Journal of Lipid Research, vol. 55, no. 2, pp. 214–225, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. K. El Harchaoui, B. J. Arsenault, R. Franssen et al., “High-density lipoprotein particle size and concentration and coronary risk,” Annals of Internal Medicine, vol. 150, no. 2, pp. 84–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. B. J. Arsenault, I. Lemieux, J.-P. Després et al., “Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size,” Clinical Chemistry, vol. 56, no. 5, pp. 789–798, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Davidson, J. M. McKenney, C. L. Shear, and J. H. Revkin, “Efficacy and safety of torcetrapib , a novel cholesterol ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels,” Journal of the American College of Cardiology, vol. 48, no. 9, pp. 1774–1781, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. C. M. Ballantyne, M. Miller, E. J. Niesor, T. Burgess, D. Kallend, and E. A. Stein, “Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study,” The American Heart Journal, vol. 163, no. 3, pp. 515.e3–521.e3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Franceschini, E. Favari, L. Calabresi et al., “Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients,” Journal of Clinical Lipidology, vol. 7, no. 5, pp. 414–422, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S. C. Lu, L. Atangan, K. W. Kim et al., “An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice,” Journal of Lipid Research, vol. 53, no. 4, pp. 643–652, 2012. View at Publisher · View at Google Scholar · View at Scopus